Abchurch has won the Financial PR remit for Verseon Corporation (AIM:VSN), the technology-based, computational drug discovery company with a market capitalisation in excess of £340 million (as at 2nd October 2015).
Based in Fremont, California, Verseon aims to revolutionise the pharmaceutical industry, by using algorithms to initially design drugs in-silico to create a regular stream of novel drugs. The Group’s main target areas are anti-coagulation, diabetic macular oedema, and solid state tumours.
The Company floated on AIM in May this year and raised £65.8m, the largest AIM pharma float at the time, and has begun expanding their US operation, with a new building purchased in August.
Julian Bosdet, Senior Partner of Abchurch commented: “Abchurch is extremely pleased to have won the brief for Verseon. The Company aims to transform the process of drug discovery and we look forward to supporting the management team in achieving this objective and keeping investors informed of the Group’s progress.”
- Ends -
Tel: +44 (0)20 7398 7701